Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Genitourinary 2Dermatologic 1

Conditions

Melanoma 15Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasm Metastasis 3Uveal Melanoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Brain Neoplasms 1

Interventions

Radiosurgery 22Ipilimumab 17Nivolumab 16pembrolizumab 11Temozolomide 9encorafenib 8dabrafenib 8binimetinib 8Magnetic Resonance Spectroscopy 6trametinib 5Bevacizumab 5CTLA-4 Antigen 4cobimetinib 3Thalidomide 3Radiotherapy 3Paclitaxel 3entrectinib 2cediranib 2Vemurafenib 2Spermine Synthase 2Specimen Handling 2Radiation 2Pemetrexed 2Opdualag 2Drug Therapy 2Carboplatin 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 214-(ethylamino)-8,9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione 2130-nm albumin-bound paclitaxel 2relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × lenvatinib × Dermatologic × Clear all
NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡